Prof. Pietro Lampertico
Singapore Hepatology Conference 2025
Singapore Hepatology Conference 2025 includes:
Thursday, 25 July 2025 – Singapore MASLD Symposium 2025 & Endoscopy Workshop
22 to 25 Aug 2025 – Singapore Hepatology Conference (covering Hepatology Topics) and the Science of HBV Cure Meeting
We are committed to delivering Short, Focused Clinical Updates on all aspects of Hepatology and Gastroenterology from the World’s leading experts.
The Live In Person Conference will be held at the Grand Hyatt Hotel, Singapore.
REGISTER HERE for the Combined Conference
To access SHC -e Resources REGISTER HERE or LOG IN (if you have previously registered for SHC)
Singapore Hepatology Conference
Welcome to Singapore Hepatology Conference Website
The second Combined GIHep and Singapore Hepatology Conference 2024 concluded on July 28, 2024. It was an outstanding success attracting over 1,500 clinicians, nurses and allied health practitioners, pharmaceutical executives and scientists.
We have uploaded the slides and videos recordings from SHC 2024, the Science of HBV Cure Meeting 2024 and the Singapore MASLD Symposium 2024 to our website.
If you were a registered attendee of the Combined GIHep and Singapore Hepatology in 2024 you can access the 2024 e-Resources without any additional charge. All you have to do is log in and you will be able to access the e-Resources from 2024 materials free of charge. If you were not a registered attendee of the Conference in 2024, you will need to register on the SHC website as a user and pay a small fee of $20.00 to help us maintain the site.
Prof. Seng Gee Lim
Conference Chairman.
Singapore Hepatology Conference
In 2025, the Singapore Hepatology Conference will be holding its conference at the Sheraton Towers Hotel from 22 August to 24 August. SHC 2025 will include:
The Singapore Hepatology Conference which is focused on short, sharp and focused updates for the busy clinician covering all aspects of liver disease that are important for clinical practice.
The Science of HBV Cure Meeting which is focused on encouraging an exchange of ideas between scientists and clinicians from academia and pharmaceutical companies in their quest for a cure to Hepatitis B.
The Singapore MASLD Symposium (SMS) which focuses on the rapid advances in treating fatty liver disease or MASLD.
The GP Symposium is a half day symposium designed to update General Practitioner on relevant clinical practises for managing liver disease in primary care.
REGISTER HERE for the Combined Conference
To access SHC -e Resources REGISTER HERE or LOG IN (if you have previously registered for SHC)
Meet Our Experts
Prof. Pietro Lampertico
Prof. MF Yuen
Prof. Jia Jidong
Prof. Jia Jidong
Prof. Jidong Jia is currently Professor of Medicine, Director of Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Professor Jia is the immediate past President of the International Association for the Study of the Liver(IASL), past President of Asian Pacific Association for the Study of the Liver (APASL 2009-2010) and Chinese Society of Hepatology (CSH 2006-2012). Professor Jia also serves as Associate Editor for Hepatology International and served as Associate Editor for Journal of Gastroenterology & Hepatology and Liver International. As a hepatologist, his clinical interests include viral, cholestatic/autoimmune and genetic liver diseases. His research work focuses mainly on cellular and molecular biology of the extracellular matrix of the liver and the pathogenesis and therapeutic study of experimental liver fibrosis. In addition, Dr. Jia has been PI or sub-PI for many clinical trials and also heavily engaged in the teaching of clinical research methodology for residents and fellows in clinical medicine. He has authored or co-authored more than one hundred papers published in national and international journals including Gastroenterology, Gut, Hepatology, and Journal of Hepatology.
Dr. Harry Janssen
Prof. Harry Janssen
Prof. Harry Janssen is a Professor of the Department of Gastroenterology and Hepatology at Erasmus MC, Rotterdam, The Netherlands.
Prof. Janssen has led numerous international multicenter clinical and translational studies on the natural history and treatment for chronic viral hepatitis and other liver diseases. His clinical and translational research aiming for immunological control and cure of hepatitis B and C has led to several globally used novel treatment concepts. He is currently the most cited global expert in chronic hepatitis B (Expertscape nr 1 among 28.932 scientists). His research contributions include sustained federal funding (greater than 20 years), over 600 peer reviewed publications, an H-index of 115, and over 60,000 citations (Google Scholar). He has acquired over $50 million USD in research funding from many different organizations among which NIH, European Commission, CIHR, NWO and ZonMW.
Dr. Chee Cheng Ean
Dr. Chee Cheng Ean
Dr. Chee Cheng Ean graduated from the University College London (UCL) Medical School, London, UK with a Bachelor of Science (Hons) in Tumour Biology in 2001 and MBBS (Lond) in 2004. She then pursued her post-graduate training in the US by completing her residency in Internal Medicine (2008) and fellowship in Haematology and Oncology (2011) at the Mayo Clinic in Rochester, Minnesota. She was also appointed as Chief Fellow of the Mayo Clinic Haematology/Oncology Fellowship Program and promoted to Assistant Professor of Medicine and Oncology during her time at Mayo Clinic. Dr Chee subsequently joined the Division of Haematology/Oncology at Case Western Reserve University in Cleveland, Ohio, USA as an attending physician and Assistant Professor of Medicine.
Her clinical research portfolio includes a novel biomarker study in colorectal cancer which was awarded institutional and national grant funding. She also developed and was Principal Investigator and national study chair of a Phase I/II US cooperative group clinical trial of a Wee1 inhibitor in pancreas cancer which received full support and endorsement by the Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) and Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) in the US. Her work in pancreas cancer lead to her appointment as the ECOG representative to the Pancreatic Cancer Task Force of the NCI Gastrointestinal Steering Committee. She has many publications in peer-reviewed journals and has been invited as a journal reviewer in her field.
Dr. Chee is a specialist in medical oncology and currently practices as a senior consultant medical oncologist and clinician scientist, and also holds the Deputy Director (Clinical) position at the National University Cancer Institute, Singapore. She is board certified by the American Board of Internal Medicine (ABIM) in Internal Medicine, Medical Oncology and Haematology.
Dr. Chee’s interests are in cancers of the gastrointestinal (GI) tract which includes colorectal cancer, liver and pancreas cancers, cancers of the biliary tract, stomach and oesophageal cancers. She is also interested in drug development of novel agents and phase I trials.
Prof. Ajay Duseja
Prof. Ajay Duseja
Dr Ajay Duseja is presently working as Professor and Head in the department of Hepatology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. He did his MBBS in 1988, MD (Internal Medicine) in 1992 and DM (Gastroenterology) from PGIMER, Chandigarh in 1996. For last more than 28 years, he is working as Faculty with focused research in the field of Hepatology.
He is Fellow of National Academy of Medical Sciences (FAMS), Fellow of American Association for the Study of Liver Diseases (FAASLD), Fellow of American College of Gastroenterology (FACG), Fellow of the Society of GI Endoscopy of India (FSGEI), Fellow of Indian Society of Gastroenterology (FISG), Fellow of Indian National Association for the Study of the Liver (FINASL) and Master of Indian Society of Gastroenterology (MISG).
He is currently the Secretary General of the Indian National Association for the Study of the Liver (INASL). He is also the National Convener of the Indian National Association for the Study of Liver (INASL) Task Force on Nonalcoholic Fatty Liver Disease (NAFLD) and the Principal Investigator of the Indian consortium on metabolic dysfunction associated
steatolic liver disease (ICOM-D) –an on-going real-life study on NAFLD in India involving 40 centres. He is the member of the Chronic Liver Disease Foundation (CLDF) NASH Committee (USA), member of Global NASH Council (USA), member of the Asia- Pacific Working Party on NAFLD and member of the Gut and Obesity in Asia (GOASIA) working group. He is also an active member of the INASL Task Force on Hepatitis C virus, Hepatitis B virus, Hepatocellular carcinoma, Alcohol-associated Liver disease and Drug Induced Liver Injury. He is the former Honorary Treasurer of INASL and has been the office bearer and member of various other scientific societies.
He is author of more than 375 papers in reputed international and national journals including 30 chapters in the Gastroenterology and Hepatology text books. His main areas of interest include metabolic dysfunction associated steatolic liver disease (MASLD), acute-on-chronic liver failure (ACLF), viral Hepatitis and hepatocellular carcinoma.
He is the Associate Editor of the Journal of Clinical and Experimental Hepatology (JCEH), an official journal of INASL. He is Principal Investigator of several extra-mural and intramural projects and is recipient of various international and national awards and honors.
Prof. Vincent Wong
Prof. Vincent Wong
MBChB (Hons), MD (CUHK), FRCP (Edin), FHKCP, FHKAM (Medicine)
Professor, Dept. of Medicine & Therapeutics Head, Div. of Gastroenterology and Hepatology
Director, Cheng Suen Man Shook Centre for Hepatitis Research Deputy Director, Center for Liver Health
Faculty of Medicine, The Chinese University of Hong Kong Honorary Consultant, Prince of Wales Hospital, Hospital Authority
Vincent Wong, MD, is a Professor in the Department of Medicine and Therapeutics at the Chinese University of Hong Kong, where he undertakes research on aspects of viral hepatitis and non-alcoholic fatty liver disease (NAFLD). Along with authoring over 350 articles in international medical journals, Prof. Wong is a pioneer in the development of hepatocellular carcinoma prediction scores and has performed important validation studies on the non-invasive assessment of NAFLD by transient elastography.
Prof. Arun Sanyal
Prof. Arun Sanyal
• Interim-Chair of the Division of Gastroenterology, Hepatology and Nutrition at Virginia Commonwealth University/VCUHealth.
• Professor of Medicine, Physiology and Molecular Pathology.
• Chair of the NIH NASH Clinical Research Network, the NIMBLE consortium and the Liver Forum for NASH and fibrosis. His research interests include all aspects of NAFLD and NASH as well as complications of cirrhosis and end stage liver disease
Prof. Rajender Reddy
Prof. Rajender Reddy
• Inaugural Founders Professor in Hepatology at the Perelman School of Medicine, University of Pennsylvannia.
• Director of Hepatology and the Medical Director of Liver Transplantation.
Click Call for Abstracts to access Abstract/Poster information and submission. Submission deadline Friday, 10 May 2025.
At the hybrid conference, an international panel of world renowned thought leaders will provide updates on the latest strategies and treatment for liver diseases.